Psychedelics
- PMID: 26841800
- PMCID: PMC4813425
- DOI: 10.1124/pr.115.011478
Psychedelics
Erratum in
-
Correction to: "Psychedelics".Pharmacol Rev. 2016 Apr;68(2):356. doi: 10.1124/pr.114.011478err. Pharmacol Rev. 2016. PMID: 26931125 Free PMC article. No abstract available.
Abstract
Psychedelics (serotonergic hallucinogens) are powerful psychoactive substances that alter perception and mood and affect numerous cognitive processes. They are generally considered physiologically safe and do not lead to dependence or addiction. Their origin predates written history, and they were employed by early cultures in many sociocultural and ritual contexts. After the virtually contemporaneous discovery of (5R,8R)-(+)-lysergic acid-N,N-diethylamide (LSD)-25 and the identification of serotonin in the brain, early research focused intensively on the possibility that LSD and other psychedelics had a serotonergic basis for their action. Today there is a consensus that psychedelics are agonists or partial agonists at brain serotonin 5-hydroxytryptamine 2A receptors, with particular importance on those expressed on apical dendrites of neocortical pyramidal cells in layer V. Several useful rodent models have been developed over the years to help unravel the neurochemical correlates of serotonin 5-hydroxytryptamine 2A receptor activation in the brain, and a variety of imaging techniques have been employed to identify key brain areas that are directly affected by psychedelics. Recent and exciting developments in the field have occurred in clinical research, where several double-blind placebo-controlled phase 2 studies of psilocybin-assisted psychotherapy in patients with cancer-related psychosocial distress have demonstrated unprecedented positive relief of anxiety and depression. Two small pilot studies of psilocybin-assisted psychotherapy also have shown positive benefit in treating both alcohol and nicotine addiction. Recently, blood oxygen level-dependent functional magnetic resonance imaging and magnetoencephalography have been employed for in vivo brain imaging in humans after administration of a psychedelic, and results indicate that intravenously administered psilocybin and LSD produce decreases in oscillatory power in areas of the brain's default mode network.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.
Figures
Similar articles
-
Hallucinogens.Pharmacol Ther. 2004 Feb;101(2):131-81. doi: 10.1016/j.pharmthera.2003.11.002. Pharmacol Ther. 2004. PMID: 14761703 Review.
-
Cardiovascular safety of psychedelic medicine: current status and future directions.Pharmacol Rep. 2023 Dec;75(6):1362-1380. doi: 10.1007/s43440-023-00539-4. Epub 2023 Oct 24. Pharmacol Rep. 2023. PMID: 37874530 Free PMC article. Review.
-
Animal models of serotonergic psychedelics.ACS Chem Neurosci. 2013 Jan 16;4(1):33-42. doi: 10.1021/cn300138m. Epub 2012 Sep 24. ACS Chem Neurosci. 2013. PMID: 23336043 Free PMC article. Review.
-
Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.Molecules. 2022 Apr 14;27(8):2520. doi: 10.3390/molecules27082520. Molecules. 2022. PMID: 35458717 Free PMC article. Review.
-
[Contribution of serotonin 5-HT2A receptor to antidepressant effect of serotonergic psychedelics].Nihon Yakurigaku Zasshi. 2023 May 1;158(3):229-232. doi: 10.1254/fpj.22141. Epub 2023 Mar 29. Nihon Yakurigaku Zasshi. 2023. PMID: 36990794 Review. Japanese.
Cited by
-
Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report.Clin Case Rep. 2024 May 28;12(6):e8791. doi: 10.1002/ccr3.8791. eCollection 2024 Jun. Clin Case Rep. 2024. PMID: 38813452 Free PMC article.
-
Effects of classic psychedelic drugs on turbulent signatures in brain dynamics.Netw Neurosci. 2022 Oct 1;6(4):1104-1124. doi: 10.1162/netn_a_00250. eCollection 2022. Netw Neurosci. 2022. PMID: 38800462 Free PMC article.
-
Long-term ayahuasca use is associated with preserved global cognitive function and improved memory: a cross-sectional study with ritual users.Eur Arch Psychiatry Clin Neurosci. 2024 May 23. doi: 10.1007/s00406-024-01817-9. Online ahead of print. Eur Arch Psychiatry Clin Neurosci. 2024. PMID: 38780800
-
The flattening of spacetime hierarchy of the N,N-dimethyltryptamine brain state is characterized by harmonic decomposition of spacetime (HADES) framework.Natl Sci Rev. 2024 Apr 4;11(5):nwae124. doi: 10.1093/nsr/nwae124. eCollection 2024 May. Natl Sci Rev. 2024. PMID: 38778818 Free PMC article.
-
The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns.Arch Toxicol. 2024 May 14. doi: 10.1007/s00204-024-03765-8. Online ahead of print. Arch Toxicol. 2024. PMID: 38743292 Review.
References
-
- Abi-Saab WM, Bubser M, Roth RH, Deutch AY. (1999) 5-HT2 receptor regulation of extracellular GABA levels in the prefrontal cortex. Neuropsychopharmacology 20:92–96. - PubMed
-
- Abuzzahab FS, Sr, Anderson BJ. (1971) A review of LSD treatment in alcoholism. Int Pharmacopsychiatry 6:223–235. - PubMed
-
- Adams KH, Hansen ES, Pinborg LH, Hasselbalch SG, Svarer C, Holm S, Bolwig TG, Knudsen GM. (2005) Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol 8:391–401. - PubMed
-
- Aghajanian GK. (1980) Mescaline and LSD facilitate the activation of locus coeruleus neurons by peripheral stimuli. Brain Res 186:492–498. - PubMed
-
- Aghajanian GK, Foote WE, Sheard MH. (1968) Lysergic acid diethylamide: sensitive neuronal units in the midbrain raphe. Science 161:706–708. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources